Connaughton Bernadette 4

What Happened Bernadette Connaughton, a director of Halozyme Therapeutics, sold a total of 1,625 shares in two open-market transactions on July 1, 2026. She disposed of 1,000 shares for $76,395 (reported at $76.39 avg.) and 625 shares for $48,256 (reported at $77.21 avg.), totaling approximately $124,651. These were sales (not purchases), and sales are commonly routine rather than an explicit bullish signal.

Key Details

• Transaction dates and prices: 2026-07-01 — 1,000 shares at $76.39 (total $76,395); 625 shares at $77.21 (total $48,256). Reported price ranges: $75.93–$76.85 and $76.95–$77.71 (weighted-average reporting noted).
• Total proceeds: ≈ $124,651.
• Shares owned after transaction: Not reported on this Form 4.
• Footnotes: Sales were made pursuant to a written Rule 10b5-1 trading plan adopted May 29, 2025 (F1). F2 and F3 note weighted-average pricing and provide price ranges; the filer can supply per-price breakdown on request.
• Timeliness: Filing appears timely (trade date 2026-07-01; Form 4 filed 2026-07-02).

Context These transactions are routine open-market sales executed under a pre-established 10b5-1 plan, which allows insiders to sell shares according to a preset schedule. Such sales do not, by themselves, indicate the director’s current view of the company’s prospects. Purchases are generally more informative for signaling insider confidence.